2025 Cell and Gene Therapy (CGT) Industry Snapshot
Posted on August 21, 2025
A Mid-Year Analysis of the Cell and Gene Therapy Market
Many are eager to understand the future of cell and gene therapies (CGTs), but the industry has faced early challenges. In response to slow adoption, some pharmaceutical companies are scaling back investments or withdrawing FDA-approved therapies from the market. Still, CGTs hold promise for patients with rare, debilitating diseases; however, high costs continue to hinder payer acceptance. In this industry snapshot, we explore the reasons behind slow CGT uptake, the current pipeline, and key considerations for payers moving forward.
Download this new CGT resource and help your organization:
- Understand contributing factors to the lower-than-expected utilization of CGTs.
- Learn more about the CGT pipeline and the primary developments shaping the CGT outlook going forward.
- Leverage essential considerations for managing your CGT strategy.
